Main Category: Diabetes
Also Included In: Pharma Industry / Biotech Industry
Article Date: 16 Nov 2010 - 4:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }());
email to a friend ? 
printer friendly ? 
opinions ? 
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that the type 2 diabetes market in Mexico will grow to $1.22 billion in 2014. Drivers of this growth include increasing prevalent population, expanding medical insurance coverage as well as the launch and use of new drugs in the market.
"Mexico now has the largest type 2 diabetes population in the world behind the United States, China, Japan and India," said Decision Resources Analyst Yannick Maneuf, Ph.D. "As the population ages, the size of Mexico's prevalent type 2 diabetes population will continue to grow. We also expect the diagnosed rate of type 2 diabetes will continue to increase as the Mexican government actively promotes early diagnosis of diabetes."
The new Emerging Markets report entitled Type 2 Diabetes in Mexico also finds that fixed-dose combination therapies constitute the largest drug-class sales with $289 million in sales in 2009 and $332 million expected in 2014. This is due to the uptake of new combinations, such as metformin plus sitagliptin (Merck's Janumet) and metformin plus pioglitazone (Rimsa's Diabamet and Eli Lilly's Competact). Surveyed physicians indicate that metformin and fixed-dosed combinations containing metformin will continue to be the most commonly used agents in Mexico through 2014.
"While metformin continues to be the most widely prescribed oral antidiabetic agent in Mexico, physicians now have more choices for their second- or third-line therapies with newly launched agents coming to market. Our primary research reveals that endocrinologists expect to use these agents more frequently in the next five years despite their high costs," added Dr. Maneuf.
Please rate this article:(Hover over the stars
then click to rate)
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
All opinions are moderated before being added.
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
No comments:
Post a Comment